ArticleJournal of the American Heart Association2026
Impact of Coronary Artery Disease Extent on GRACE Risk Score Prognostic Performance After ST-Segment-Elevation Myocardial Infarction.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe GRACE (Global Registry of Acute Coronary Events) score is well validated for risk stratification in non-ST-segment-elevation myocardial infarction, but less well established in ST-segment-elevation myocardial infarction (STEMI), particularly relative to coronary disease burden. We therefore assessed its prognostic performance in a STEMI cohort, accounting for baseline coronary disease extent.
methodsWe studied 1099 patients with STEMI from the CardioLines Coronary Biobank (2015-2021) with evaluable GRACE score and follow-up data. Patients were stratified by the number of coronary vessels with significant stenosis. The primary end point was all-cause death at 1 year; the secondary end point was a combined end point, including all-cause death, recurrent acute coronary syndrome, stroke, and revascularization at 1 year.
resultsMean GRACE scores increased with the number of diseased vessels (
conclusionsIn this contemporary STEMI cohort, the GRACE score effectively stratifies event risk in single-vessel but performs poorly in multivessel disease. These findings suggest variable prognostic utility of the GRACE score across anatomic disease burden post-STEMI and caution when applying it across STEMI subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.